Cabio Biotech Wuhan Co Ltd (688089) — Strategic Asset Allocation Index
Cabio Biotech Wuhan Co Ltd (688089) has a Strategic Asset Allocation Index of 37.1% as of June 2023. Strategic assets (PP&E of CN¥534.05 Million plus long-term investments of CN¥-) total CN¥534.05 Million, measured against net assets of CN¥1.44 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Cabio Biotech Wuhan Co Ltd to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Cabio Biotech Wuhan Co Ltd Strategic Asset Allocation Index (2019–2022)
This chart shows how Cabio Biotech Wuhan Co Ltd's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of June 2023, the index stands at 37.1%, representing strategic assets of CN¥534.05 Million against net assets of CN¥1.44 Billion CNY. For live market cap and overall valuation, see market value of Cabio Biotech Wuhan Co Ltd.
Annual Strategic Asset Allocation Index for Cabio Biotech Wuhan Co Ltd (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Cabio Biotech Wuhan Co Ltd from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 688089 book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 34.1% | CN¥485.96 Million | CN¥485.96 Million | CN¥- | CN¥1.43 Billion | ▲ +16.6 pp |
| 2021 | 17.5% | CN¥241.93 Million | CN¥241.93 Million | CN¥- | CN¥1.38 Billion | ▲ +6.2 pp |
| 2020 | 11.3% | CN¥149.51 Million | CN¥149.51 Million | CN¥- | CN¥1.32 Billion | ▼ -1.8 pp |
| 2019 | 13.1% | CN¥163.71 Million | CN¥163.71 Million | CN¥- | CN¥1.25 Billion | — |